Conestoga Capital Advisors LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 1.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,546,168 shares of the company’s stock after purchasing an additional 15,353 shares during the period. Omnicell comprises approximately 3.5% of Conestoga Capital Advisors LLC’s holdings, making the stock its 3rd largest holding. Conestoga Capital Advisors LLC owned approximately 3.75% of Omnicell worth $124,992,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Omnicell by 27.9% in the third quarter. Vanguard Group Inc. now owns 3,806,211 shares of the company’s stock worth $273,665,000 after purchasing an additional 830,338 shares during the last quarter. Vanguard Group Inc raised its position in Omnicell by 27.9% during the third quarter. Vanguard Group Inc now owns 3,806,211 shares of the company’s stock valued at $273,665,000 after acquiring an additional 830,338 shares in the last quarter. Bank of New York Mellon Corp raised its position in Omnicell by 2.5% during the third quarter. Bank of New York Mellon Corp now owns 946,239 shares of the company’s stock valued at $68,035,000 after acquiring an additional 22,890 shares in the last quarter. Geode Capital Management LLC raised its position in Omnicell by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 442,184 shares of the company’s stock valued at $27,079,000 after acquiring an additional 32,512 shares in the last quarter. Finally, Tributary Capital Management LLC raised its position in Omnicell by 1.3% during the first quarter. Tributary Capital Management LLC now owns 330,204 shares of the company’s stock valued at $26,694,000 after acquiring an additional 4,153 shares in the last quarter. Institutional investors and hedge funds own 95.55% of the company’s stock.
Several analysts have commented on OMCL shares. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a report on Monday, March 25th. Craig Hallum lowered Omnicell from a “buy” rating to a “hold” rating and set a $84.00 price objective on the stock. in a report on Friday, April 26th. BidaskClub raised Omnicell from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. TheStreet lowered Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. Finally, ValuEngine raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Omnicell has a consensus rating of “Buy” and a consensus price target of $79.89.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.38. The firm had revenue of $202.50 million for the quarter, compared to the consensus estimate of $199.72 million. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 2.06 earnings per share for the current fiscal year.
In other news, EVP Dan S. Johnston sold 8,210 shares of the company’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $81.16, for a total transaction of $666,323.60. Following the completion of the transaction, the executive vice president now directly owns 36,504 shares of the company’s stock, valued at approximately $2,962,664.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Randall A. Lipps sold 24,282 shares of the company’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $79.01, for a total value of $1,918,520.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 188,916 shares of company stock worth $14,362,850. 2.77% of the stock is owned by company insiders.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.